LumineticsCore
Diabetic Retinopathy
ApprovedActive
Key Facts
About Digital Diagnostics
Digital Diagnostics is a leader in autonomous AI diagnostics, holding the historic first FDA clearance for an AI system that autonomously diagnoses diabetic retinopathy. The company's core technology, LumineticsCore, is a reimbursable, 30-second diagnostic tool deployed in primary care settings to close the significant care gap in annual diabetic eye exams. By enabling diagnosis outside of specialty clinics, Digital Diagnostics aims to prevent vision loss, improve healthcare efficiency, and address systemic health disparities. The company is generating real-world evidence through commercial deployments and is positioned to expand its platform into new diagnostic areas.
View full company profileTherapeutic Areas
Other Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (DR) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| NOX4 Inhibitor (GLX7013114) | Glucox Biotech | Preclinical |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| jCell (RPCs) | jCyte | Preclinical |
| Diabetic Retinopathy Program | Lxbio Pharmaceuticals | Pre-clinical |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical |
| NBP-14 and derivatives | Neuro Bio | Research |
| Vasculogenic Cell Therapy | Vascugen | Pre-clinical |
| Danegaptide | Breye Therapeutics | Phase 2 |
| OcuRetina | Oculotix | Phase 2 |
| YH14618 | Yuhan | Phase 2 |